Nasdaq · Healthcare
ClearPoint Neuro, Inc. (CLPT)
As-reported financials and recent SEC filings for ClearPoint Neuro, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$37.0M
Net income
$-25.5M
Net margin
-69.1%
Diluted EPS
$-0.90
ROE
-91.1%
P/E (TTM)
—
Market cap
—
Debt / equity
1.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $37.0M | $31.4M | $24.0M | $20.6M | $16.3M |
| Gross profit | $22.7M | $19.1M | $13.6M | $13.5M | $11.1M |
| Operating income | $-24.2M | $-19.7M | $-22.4M | $-16.3M | $-13.4M |
| Net income | $-25.5M | $-18.9M | $-22.1M | $-16.4M | $-14.4M |
| Diluted EPS | $-0.90 | $-0.70 | $-0.90 | $-0.68 | $-0.69 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-06
View on EDGAR →42026-07-06
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-01
View on EDGAR →1442026-06-29
View on EDGAR →42026-06-22
View on EDGAR →Largest Healthcare peers
Go deeper on CLPT
Search ClearPoint Neuro, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.